Literature DB >> 32017522

Targeted Covalent Inhibition of Telomerase.

Rick C Betori1, Yue Liu2, Rama K Mishra3, Scott B Cohen4, Stephen J Kron2, Karl A Scheidt1,5,3.   

Abstract

Telomerase is a ribonuceloprotein complex responsible for maintaining telomeres and protecting chromosomal integrity. The human telomerase reverse transcriptase (hTERT) is expressed in ∼90% of cancer cells where it confers the capacity for limitless proliferation. Along with its established role in telomere lengthening, telomerase also serves noncanonical extra-telomeric roles in oncogenic signaling, resistance to apoptosis, and enhanced DNA damage response. We report a new class of natural-product-inspired covalent inhibitors of telomerase that target the catalytic active site.

Entities:  

Year:  2020        PMID: 32017522      PMCID: PMC7233141          DOI: 10.1021/acschembio.9b00945

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  108 in total

1.  Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex.

Authors:  Mu-Yong Kim; Hariprasad Vankayalapati; Kazuo Shin-Ya; Konstanty Wierzba; Laurence H Hurley
Journal:  J Am Chem Soc       Date:  2002-03-13       Impact factor: 15.419

2.  Enantioselective synthesis of (-)-exiguolide by iterative stereoselective dioxinone-directed Prins cyclizations.

Authors:  Erika A Crane; Thomas P Zabawa; Rebecca L Farmer; Karl A Scheidt
Journal:  Angew Chem Int Ed Engl       Date:  2011-09-19       Impact factor: 15.336

3.  Inhibitory effects of costunolide on the telomerase activity in human breast carcinoma cells.

Authors:  Sang-Ho Choi; Eunok Im; Hyun Kyung Kang; Ji-Hyeon Lee; Hi-Suk Kwak; Young-Tae Bae; Hee-Juhn Park; Nam Deuk Kim
Journal:  Cancer Lett       Date:  2005-09-28       Impact factor: 8.679

4.  Hydrogen bond catalyzed enantioselective vinylogous Mukaiyama aldol reaction.

Authors:  Vijaya Bhasker Gondi; Michel Gravel; Viresh H Rawal
Journal:  Org Lett       Date:  2005-12-08       Impact factor: 6.005

5.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.

Authors:  Jonathan B Baell; Georgina A Holloway
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

Review 6.  The role of double-strand break repair pathways at functional and dysfunctional telomeres.

Authors:  Ylli Doksani; Titia de Lange
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-09-16       Impact factor: 10.005

7.  Total synthesis and structure-activity investigation of the marine natural product neopeltolide.

Authors:  Daniel W Custar; Thomas P Zabawa; John Hines; Craig M Crews; Karl A Scheidt
Journal:  J Am Chem Soc       Date:  2009-09-02       Impact factor: 15.419

8.  Total synthesis and structural revision of the marine macrolide neopeltolide.

Authors:  Daniel W Custar; Thomas P Zabawa; Karl A Scheidt
Journal:  J Am Chem Soc       Date:  2008-01-23       Impact factor: 15.419

9.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

10.  Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects.

Authors:  Jonathan Z Long; Weiwei Li; Lamont Booker; James J Burston; Steven G Kinsey; Joel E Schlosburg; Franciso J Pavón; Antonia M Serrano; Dana E Selley; Loren H Parsons; Aron H Lichtman; Benjamin F Cravatt
Journal:  Nat Chem Biol       Date:  2008-11-23       Impact factor: 15.040

View more
  2 in total

Review 1.  Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.

Authors:  Jixuan Gao; Hilda A Pickett
Journal:  Nat Rev Cancer       Date:  2022-07-05       Impact factor: 69.800

2.  In Silico Design, Synthesis, and Biological Evaluation of Anticancer Arylsulfonamide Endowed with Anti-Telomerase Activity.

Authors:  Giulia Culletta; Mario Allegra; Anna Maria Almerico; Ignazio Restivo; Marco Tutone
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.